Compare Agnico Eagle Mines Ltd (AEM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Merck & Co., Inc. — how do they compare? Agnico Eagle Mines Ltd trades at $144.63 (market cap $75.10B), while Merck & Co., Inc. trades at $126.57 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 4.2× Agnico Eagle Mines Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| AEM | MRK | |
|---|---|---|
Market Cap | $75.10B | $318.26B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $129.52 |
52-Week Low | $116.14 | $77.60 |
Enterprise Value | $72.30B | $361.68B |
Dividend Yield | 1.2% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
Merck (MRK) trades at $126.61, down slightly by 0.13% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The stock offers upside to the consensus price target of $139.33, driven by earnings momentum and expansion in high-margin drugs, but faces risks from patent expirations, regulatory scrutiny, and integration challenges from acquisitions. Investors should weigh the strong analyst buy rating (67.57%) against potential volatility from macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
